Physician profile
Ming L Tsang
NPI 1497855159
$45,096.20
in general payments reported to CMS, 2019-2025
62 companies · $5,830 in 2025
The $5,830 reported for 2025 was more than what 99% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $14K · 2020: $4,703 · 2021: $4,766 · 2022: $4,937 · 2023: $4,801 · 2024: $6,136 · 2025: $5,830.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $17K · Education: $19.28.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $16,747.80 |
| Education | $19.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $13,406.79 | 2019-2025 | Biktarvy, Yeztugo |
| Viiv Healthcare Company | $4,687.35 | 2019-2025 | Cabenuva, Apretude, Dovato |
| Astrazeneca Pharmaceuticals LP | $3,231.64 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Abbvie INC. | $2,933.10 | 2019-2025 | Vraylar, Ubrelvy, Linzess |
| Boehringer Ingelheim Pharmaceuticals, INC. | $2,546.50 | 2019-2025 | Jardiance, Ofev, Jascayd |
| Glaxosmithkline, LLC. | $1,866.88 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Novo Nordisk INC | $1,645.73 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $1,462.18 | 2019-2025 | |
| Lilly USA, LLC | $1,279.04 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Takeda Pharmaceuticals U.S.A., INC. | $1,000.20 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $987.67 | 2019-2025 | Xifaxan, Trulance |
| Merck Sharp & Dohme LLC | $976.05 | 2019-2025 | Gardasil 9, Capvaxive, Delstrigo |
| Amgen INC. | $809.20 | 2019-2025 | Repatha, Otezla, Tavneos |
| Axsome Therapeutics, INC. | $801.24 | 2023-2025 | Auvelity |
| Bayer Healthcare Pharmaceuticals INC. | $782.75 | 2021-2025 |
Show all 62 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ming Tsang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.